Selected Publications
Selected Publications
2023
Sheikh A, Zechmann B, Sayes CM, Taube JH, Greathouse KL. A preparation of bacterial outer membrane with osmium tetroxide and uranyl acetate co-stain enables improved structural determination by transmission electron microscopy. Microscopy (Oxf) (2023)
Reisenauer KN, Aroujo J, Tao Y, Ranganathan S, Romo D, Taube JH. Therapeutic vulnerabilities of cancer stem cells and effects of natural products. Natural Product Reports (2023)
2021
Song S, Johnson KS, Lujan H, Pradhan SH, Sayes CM, Taube J. Nanoliposomal delivery of microRNA-203 suppresses migration of triple-negative breast cancer through distinct target suppression. ncRNA (2021)
Xue H, Svatek H, Berthona A, Reisenauer K, Robinson J, Kim M, Ingros A, Ho M, Taube J, Romo D. Synthesis of Agelastatin A and Derivatives Premised on a Hidden Symmetry Element Leading to Analogs Displaying Anticancer Activity Tetrahedron (2021)
Sheikh A, Taube J, Greathouse L. Contribution of the Microbiota and their Secretory Products to Inflammation and Colorectal Cancer Pathogenesis: The Role of Toll-like Receptors Carcinogenesis (2021)
Reisenauer K, Tao Y, Das P, Song S, Svatek H, Patel S, Mikhail S, Ingros A, Sheesley P, Evidente A, Kornienko A, Romo D, Taube J. Epithelial-mesenchymal transition sensitizes breast cancer cells to cell death via the fungus-derived sesterpenoid, Ophiobolin A Scientific Reports (2021)
2020
Tao Y, Reisenauer K, Marco M, Evidente A, Taube JH,* and Romo D*, Pharmacophore-Directed Retrosynthesis Applied to Ophiobolin A: Simplified Bicyclic Derivatives Displaying Anticancer Activity Organic Letters (2020)
Das, P, Taube JH. Regulating Methylation at H3K27: a Trick or Treat for Cancer Cell Plasticity Cancers, 12(10), 2792; (2020) [link]
Kalecky K, Modisette R, Pena S, Cho Y-R, Taube JH. Integrative analysis of breast cancer profiles in TCGA by TNBC subgrouping reveals novel microRNA-specific clusters, including miR-17-92a, distinguishing basal-like 1 and basal-like 2 TNBC subtypes. BMC Cancer, 20:141 (2020) [link]
2019
Tao Y, Reisenauer K, Taube JH, Romo D. Total Synthesis and Anticancer Activity of (+)-Hypercalin C and Congeners. Angewandte Chemie, 58, 2734 –2738. (2019). [link]
Lujan H, Griffin W, Taube JH, Sayes CM. Synthesis and characterization of nanometer sized liposomes for encapsulation and the effects on breast cancer cells. International Journal of Nanomedicine 14 5159–5173 (2019) [link]
2018
Eyong K, Bairy G, Eno A, Taube JH, Hull K, Folefoc G, Foyet H, Romo D. Triterpenoids from the stem bark of Vitellaria paradoxa (Sapotaceae) and derived esters exhibit cytotoxicity against a breast cancer cell line. Medicinal Chemistry Research, Volume 27, Issue 1, pp 268–277 (2018) [link]
Sidjui L, Eyong K, Hull K, Folefoc G, Leddet V, Herbette G, Ollivier E, Taube JH, Klausmeyer K, Romo D. Bioactive Lanostane-Type Triterpenoids from the Root of Leplaea Mayombensis (Meliaceae). Journal of Natural Products, Volume 80, Issue 10, 27 October 2017, Pages 2644-2651 (2017) PMID: 28945373. [link]
2017
Hodges S, Nolan S, Taube J, Lugo J. Adult Fmr1 knockout mice present with deficiencies in hippocampal IL-6 and TNFα expression. Neuroreport. Dec 13;28(18):1246-1249 (2017) PMID: 28915148 [link]
Taube JH*#, Sphyris N*, Johnson K, Reisenauer K, Nesbit TA, Joseph R, Vijay GV, Sarkar TR, Bhangre NA, Song JJ, Chang JT, Lee MG, Soundararajan R, Mani SA#. *co-first authors #co-corresponding authors The H3K27me3-demethylase KDM6A is suppressed in breast cancer stem-like cells, and enables the resolution of bivalency during the mesenchymal-epithelial transition. Oncotarget. (2017). Demonstrates a novel role for KDM6A in reversible EMT. [link]
2016
Werden SJ, Sphyris N, Sarkar TR, Paranjape AN, LaBaff AM, Taube JH, Hollier BG, Ramirez-Peña EQ, Soundararajan R, den Hollander P, Powell E, Echeverria GV, Miura N, Chang JT, Piwnica-Worms H, Rosen JM, and Mani SA. Phosphorylation of serine 367 of FOXC2 by p38 regulates ZEB1 and breast cancer metastasis, without impacting primary tumor growth. Oncogene 35, 5977–5988 (2016). [link]
Paranjape AN, Soundararajan R, Werden SJ, Joseph R, Taube JH, Liu H, Rodriguez-Canales J, Sphyris N, Wistuba I, Miura N, Dhillon J, Mahajan N, Mahajan K., Chang JT, Ittmann M, Maity SN, Logothetis C, Tang DG, Mani SA. Inhibition of FOXC2 restores epithelial phenotype and drug sensitivity in prostate cancer cells with stem-cell properties. Oncogene. 35, 5963–5976 (2016). [link]
Dhawan A*, Tonekaboni SAM*, Taube JH*, Hu S, Sphyris N, Mani SA & Kohandel M. *co-first authors Mathematical modelling of phenotypic plasticity and conversion to a stem-cell state under hypoxia. Scientific Reports. (2016). PMID: 26838463 PMCID: PMC4738268 [link]
2013
Taube, JH Malouf GG, Lu E, Sphyris N, Vijay V, Ramachandran PR, Ueno K, Gaur S, Nicoloso M, Rossi S, Herschkowitz JI, Rosen JM, Issa J-PJ, Calin GA, Chang JT, Mani SA. Epigenetic silencing of microRNA-203 is required for EMT and cancer stem cell properties. Sci. Rep. 3, 2687 (2013). [link] Demonstrated a novel link between microRNA-203 and cancer stem cell properties, prompting further work on this microRNA as mediator of differentiation therapy.
Malouf GG*, Taube JH*, Lu Y, Roysarkar T, Panjarian S, Estecio MR, Jelinek J, Yamazaki J, Raynal NJ, Long H, Tahara T, Tinnirello A, Ramachandran P, Zhang XY, Liang S, Mani SA, Issa JP. *co-first authors Architecture of epigenetic reprogramming following Twist1-mediated epithelial-mesenchymal transition. Genome Biol. 24;14 (12) (2013). [link] Demonstrated the genome-wide epigenetic alterations associated with EMT.
2010
Taube JH.*, Herschkowitz J.*, Komurov K.*, Zhou A., Yang J., Hartwell K., Onder T., Gupta P., Evans K., Hollier B., Ram P., Lander E., Rosen J., Weinberg R., and Mani S. *co-first authors A Core EMT Interactome Gene Expression Signature is Associated with Claudin-low and Metaplastic Breast Cancer Subtypes. PNAS Nov 2; 107(44):19132. (2010). [link] Demonstrated a foundational link between EMT and triple-negative breast cancer subtypes. >500 citations.